Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cole Werble

Washington, DC
Cole Werble is the former owner and editorial director of FDC Reports, Inc., the publisher of The Pink Sheet, The Gray Sheet, and other leading news publications for the health care industry. He has more than 35 years of experience analyzing business critical developments affecting the biopharma sector and developing world class information products for the sector.
Advertisement
Set Alert for Articles By Cole Werble

Latest From Cole Werble

Pivot To Video? “Netflix” Rx Pricing Model Plays Well With Media

A subscription model for drug pricing isn’t an entirely new idea, but it is a timely one. If nothing else, the idea of a “Netflix” approach appeals to media savvy audiences. 
Pricing Debate Pricing Strategies

XLH Patient Meeting Showcases Value Of Post-Approval Feedback To US FDA

X-Linked Hypophosphatemia patient feedback meeting follows recent approval of Ultragenyx’ Crysvita. Like an SMA meeting in 2017, it showed how post-approval meetings can help sustain momentum in a new class.
Rare Diseases Approvals

Cleveland Clinic “Outsourcing”? 503B Status Would Be Milestone For US FDA’s Compounding Model

Chronic problem with drug shortages is driving the Cleveland Clinic to consider registering as a 503B “outsourcing” facility. That could be a milestone in FDA’s efforts to encourage the model for high volume compounders.

The Economics Of Drug Shortages: US FDA Seeks Broad Input

FDA is planning series of stakeholder meetings to identify new approaches to drug shortages, with particular interest in defining “essential” drugs. Agency is also looking outside for expertise, with Boston University’s Rena Conti tapped as advisor.
Manufacturing Regulation

Breathing Life Into Inhaled Antibiotics: US FDA Tries To Move Class Ahead After Two Rejections

Workshop on inhaled antibiotics serves as unusual post mortem after two public rejections at advisory committee level; agency clearly eager not to see development in field end.  
Infectious Diseases Drug Approval Standards

MedPAC Analysis Of 'Low-Value' Medicare Treatments Spotlights Acthar

The Medicare Payment Advisory Commission’s annual 2018 report to Congress features the flip side of the recent value-based rhetoric – highlighting “low-value” Medicare purchases. The drug chosen to make that argument is Mallinckrodt’s HP Acthar Gel.   

Pricing Debate Medicare
See All
Advertisement
UsernamePublicRestriction

Register